GSE162892 3 V 1 ISOX HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE162892 3 V 1 ISOX HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE162892 3 V 1 ISOX HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE162892 3 V 1 ISOX HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE162892 3 V 1 ISOX HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

small integral membrane protein 44

Gene

family with sequence similarity 90 member A24

Gene

transmembrane protein 217B

Gene

speedy/RINGO cell cycle regulator family member E18

Gene

myosin XVB

Gene

torsin family 1 member B

Gene

spermatogenesis associated 18

Gene

shiftless antiviral inhibitor of ribosomal frameshifting

Gene

phosphate regulating endopeptidase X-linked

Gene

vitelline membrane outer layer 1 homolog

  • Gene

    small integral membrane protein 44


  • Gene

    family with sequence similarity 90 member A24


  • Gene

    transmembrane protein 217B


  • Gene

    speedy/RINGO cell cycle regulator family member E18



  • Gene

    torsin family 1 member B


  • Gene

    spermatogenesis associated 18


  • Gene

    shiftless antiviral inhibitor of ribosomal frameshifting


  • Gene

    phosphate regulating endopeptidase X-linked


  • Gene

    vitelline membrane outer layer 1 homolog

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.